Buy the full study
Summary of our market study
In France, the market for aesthetic medicine and surgery is worth around 10 to 15 billion euros.
The global market for aesthetic surgery and medicine is estimated at $127 billion in 2023.
Growth is being driven by technological innovations in aesthetic devices, increasing non-invasive treatment options and growing acceptance of aesthetic procedures, particularly in the Asia-Pacific region.
The United States accounted for 45% of the market.
In France, the market is growing at an annual rate of over 10-20%.
More than 300,000 cosmetic surgery operations and over 400,000 aesthetic medicine procedures performed in 2022
Non-surgical procedures such as hyaluronic acid and botulinum toxin injections are on the rise
The number of people having procedures is between 1 and 2 million.
Demand for aesthetic services in France is strongly influenced by the fact that the boundary between aesthetics and medicine is blurring. Aesthetic medicine now accounts for around 50% of the market for aesthetic procedures.
France boasts a number of manufacturers specializing in the aesthetic surgery and cosmeceuticals segments.
Players in the French aesthetic medicine and surgery market
- Allergan: A long-standing player
- Eurosilicone (GC Aesthetics) and Laboratoires Sebbin: These two companies manufacture breast implants.
- Laboratoires Vivacy: Specializing in aesthetic and anti-aging products.
- L'Oréal and its Active Cosmetics division, with Skinceuticals, Vichy and La Roche-Posay, is at the forefront of the cosmeceuticals segment.
- Deleo: The company specializes in cryolipolysis equipment and high-power LED lamps.
- Merz is known for its BoCouture product
- Galderma plays a crucial role with its botulinum toxin product Azzalure.
- Syneron-Candela and Lumenis: These international players occupy a strong position in the supply of energy-based devices
to understand this market
Detailed content of our market study
Inforamtion
- Number of pages : ~ 40 pages
- Format : Digital and PDF versions
- Last update :
Summary and extracts
1 Market overview
1.1 Definitions and market overview
The aesthetic medicine and surgery market in France comprises several distinct segments[La Roche Posay; Le Figaro Santé] :
Aesthetic surgery
A speciality of plastic surgery, this technique of reshaping the body through surgical intervention corrects a morphological anomaly or the outward appearance of a patient's body. The results are radical .
Among the most common procedures are[Fashion4mec]:
- Facial surgery: cervico-facial lift, rhinosplasty (nose), blepharoplasty (eyelids).
- Breast surgery: breast augmentation, breast reduction, breast reconstruction, breast implant replacement.
- Body surgery: abdominoplasty, liposuction, lipomodelling, intimate surgery.
Aesthetic medicine
This covers all non-surgical advice, care and treatment designed to improve a patient's aesthetic appearance. Described as "non-invasive", the vast majority of procedures involve injections under the skin, for example to reduce wrinkles. The result of a procedure is temporary and reversible. Aesthetic medical procedures must therefore be repeated to maintain their benefits .
The most common procedures include[CR] :
- hyaluronic acid injection
- botulinum toxin injections
- tightening or lifting threads
- cryolipolysis (cold fat removal)
- laser hair removal
- peeling (exfoliation/dermo-epidermal stimulation)
- hair transplant
Cosmeceuticals
Halfway between cosmetics and drugs, cosmeceuticals contain active ingredients for specific dermatological treatments (wrinkles, dark circles, etc.). Cosmeceuticals are most frequently used to correct skin aging, although their efficacy has yet to be proven.
The first breast augmentations were performed in the 1950s/1960s, just as lasers were making their appearance in dermatology. Later, in the 80s, Dr Gérard Yllouz revolutionized cosmetic surgery by inventing liposuction. Finally, in the 90s and 2000s, aesthetic medicine emerged with the development of botox and hyaluronic acid.[Reau]
The global market for aesthetic surgery and medicine is booming, driven in particular by the dynamism of the Asian regions, which are currently the main focus of global demand. However, the market is still largely dominated by the United States and Brazil, and is valued at $127.1 billion in 2023, rising at a CAGR of14.7% from 2023 to 2030, to reach $332.1 billion. This growth is due in part to the boom in injectable substances, to the renewal of equipment and technologies required for operations, but also to the dual context of an ageing population and growing acceptance of cosmetic surgery. [GV]
The French market is also growing, thanks in particular to the growing popularity of aesthetic medicine methods, which straddle the line between medical treatment and simple cosmetic surgery.the French market is also growing, thanks in particular to the growing popularity of aesthetic medicine methods, which straddle the line between medical treatment and simple aesthetic procedures, to the detriment of in-clinic surgical procedures whose popularity has been affected by a number of scandals. The French aesthetics market will be worth 12 billion euros by 2021, with average annual growth of 15% from 2018 until at least 2024. [Clinique des Champs Elysées]
According to Le Figaro,more than 320,000 cosmetic surgery and 420,000 aesthetic medicine procedures were carried out in the country in 2022.As a result, the number of French people who have already had cosmetic surgery is estimated to have risen by 13% in one year, to 1.4 million.
Lastly, the legal framework plays a key role in regulating the market and authorizing certain practices. It therefore plays a decisive role in understanding market supply and major market dynamics [France Tv].
1.2 A fast-growing global market
The global market for aesthetic surgery and medicine is valued at $***.* billion in ****, and is expected to grow at a CAGR of **.*% from **** to ****, reaching $***.* billion. Innovation in aesthetic devices over the past decade has driven growth in demand for aesthetic treatments.
The introduction of technically advanced products, such as non-invasive ...
1.3 The French market
The French aesthetics market will be worth ** billion euros by ****, with average annual growth of **% from **** until at least ****. [***]
According to Le Figaro,more than ***,*** cosmetic surgery and ***,*** aesthetic medicine procedures were carried out in the country in ****.The number of French people who have already had cosmetic surgery is estimated ...
1.4 The phenomenon of patients fleeing abroad
Mexico, Turkey and Colombia recorded the highest proportion of foreign patients: **.*%, **.*% and **.*% respectively in ****. Thailand, which ranked first in ****, was fourth, with **.*%. Figures for **** are not revealed by ISAPS, but these four countries remain those with the highest proportion of foreign patients. [***]
Ranking of countries with the most foreign patients for ...
2 Demand analysis
2.1 Socio-demographic factors driving market growth
In France, demand in the aesthetics market has been growing steadily for several decades, thanks to various socio-demographic factors such as an aging population, the growing importance of physical appearance in French society, a steadily increasing female population, and the expansion of the market to include men and young people.these ...
2.2 Demand driven by a small part of the population
However, demand is very intensely concentrated in a small proportion of the population that carries the aesthetic market. Indeed, as shown in the graph below, which incorporates the results of an IFOP survey carried out in June **** in France, the proportion of people considering cosmetic surgery or medicine was already very ...
2.3 The most popular operations
The International Public Sector Accounting Standards (***) has released its **** report on the global aesthetic care business. In order to obtain more recent and accurate data on certain products, we will study the data in this report.
Breakdown of most popular surgical procedures World, ****, as % of total Source: ****
In terms of aesthetic ...
3 Market structure
3.1 A market structured around equipment manufacturers and practitioners
There are two main types of players in the aesthetic medicine and surgery market: upstream manufacturers of equipment for aesthetic purposes, and downstream practitioners or treatment establishments.
*) Equipment manufacturers
The French market for manufacturers is characterized by a high degree of specialization, due to the demanding technology and cost of ...
3.2 Production of medical and cosmetic surgery equipment
The production of aesthetic equipment includes breast prostheses, injectables, equipment and cosmeceuticals. As the aesthetic market requires high entry costs and cutting-edge technology, most manufacturers specialize in one of these segments.
As the main market players are international groups, the majority of production sites are located abroad, with the exception of ...
3.3 A trend towards diversification
Players in the distribution market
The aesthetic products distribution market comprises three main types of player: the group in charge of production, a subsidiary of the group specialized in distribution, and finally a wholesaler specialized in the distribution of aesthetic medicine and surgery products.
The integrated model, in which the company ...
3.4 Multi-channel distribution and growing consumer autonomy
Thegrowth of various distribution channels has prompted manufacturers to gear their distribution towards a multi-channel strategy. Today, the main distribution channels on the rise are selective perfumeries, web merchants, mail order and large-scale distribution specialized in home appliances. Talika's home devices, for example, have been sold since **** at Marionnaud and in ...
4 Offer analysis
4.1 Typology of aesthetic medicine services
Aesthetic medicine
In France, aesthetic medicine was mainly composed of injection procedures (***) [***]. The census of procedures carried out in France dates from ****, but there have been no drastic changes since then, so the figures still make sense in ****.
Wrinkle-filling injections, on the other hand, are much less regulated, allowing over *** brands ...
4.2 Prices for aesthetic medicine services
According to the French Association of Aesthetic and Anti-Aging Medicine (***), average prices for various aesthetic medicine procedures on the silhouette by the end of **** are as follows:
Source: ****
For cosmetic surgery on the body, the results are as follows:
Source: ****
Prices for cosmetic surgery on the face and neck are as ...
5 Regulations
5.1 Regulations governing aesthetic medicine and surgery
Law no. ****-*** of March *, ****, on patients' rights and the quality of the healthcare system, also known as the Kouchner law, is partly intended to regulate the practice of aesthetic medicine and surgery. [***]
The quality and safety of care are thus ensured by :
*) Controlling surgeons' competence[***]
The practice of aesthetic ...
5.2 Even stricter regulations in the wake of the PIP scandal
The medical and cosmetic surgery market continues to grow despite the PIP affair, which began in in ****, when the prostheses were withdrawn from the market following the first case of cancer detected due to anomalies in the product. In ****, the certifying body for these prostheses, TÜV, was ordered to pay ...
6 Positioning the players
6.1 Segmentation
- Allergan plc
- Galderma
- Merz Pharmaceuticals
- La Roche-Posay
- Filorga Cosmétiques (Colgate Palmolive)
- Lierac (Laboratoire Native)
- Laboratoires Sebbin
- Arion
- Candela Medical
- Deleo
- Ipsen
- Clinique des Champs Elysées
- Lazeo
- Maison Lutetia
- Skincareagency
List of charts presented in this market study
- The global aesthetic medicine market by value
- Number of interventions by type
- Beauty care market sales, APE code 96.02B
- Population projections to 2070
- Proportion of French population aged 65 and over
All our studies are available online in PDF format
Take a look at an example of our research on another market!
Latest news
Ten years after its exit, L'Oréal re-acquires a stake in Galderma - 06/08/2024
- - In early 2014, L'Oréal sold its 50% stake in Galderma to Nestlé.
- - Galderma achieved its biggest IPO on the Zurich Stock Exchange since 2017, with a capitalization of 17 billion euros.
- - Galderma's sales have risen from 1.6 billion euros in 2014 to 4.1 billion euros in 2024.
- - L'Oréal's investment to acquire 10% of Galderma's capital would amount to 1.7 billion euros.
- - In 2019, Galderma is acquired by a consortium led by the Swedish fund EQT and a subsidiary of the sovereign wealth fund Abu Dhabi Investment Authority for 9.3 billion euros.
L'Oréal launches into injectable aesthetics by investing in Swiss company Galderma - 06/08/2024
- - L'Oréal stake in Galderma: 10%
- - Share of Galderma's worldwide sales generated by injectable aesthetics: 50%
- - Galderma sales growth in one year: 8.5
- - Injectable aesthetics market: strong growth
Swiss dermatology laboratory Galderma floats on the stock market - 07/03/2024
- - Galderma was founded in 1981 by Nestlé and L'Oréal.
- - EQT took over Galderma in 2019 and plans to list Galderma on the Zurich Stock Exchange.
- - Galderma targets capital raising of around $2.3 billion
- - Galderma is based in Zug, Switzerland, and employs 6,500 people worldwide, including 500 in France.
- - Galderma presents itself as a "pure player" in dermatology, with its Cetaphil cosmetics brand.
- - Sales of Cetaphil are expected to exceed $1 billion by 2023, a quarter of Galderma's sales for the same year ($4.1 billion).
- - EQT acquired Galderma from Nestlé in 2019 for 10.2 billion Swiss francs (10.6 billion euros).
This skincare specialist was co-founded in 1981 by L'Oréal and Nestlé. - 06/03/2024
- Galderma sales exceeded $4 billion for the first time.
- Galderma was created in 1981 by L'Oréal and Nestlé.
- In 2014, Nestlé became Galderma's sole shareholder. at that time, Galderma generated sales of €1.6 billion.
- In 2019, a consortium led by Swedish fund EQT and a subsidiary of sovereign wealth fund Abu Dhabi Investment Authority acquired Galderma for 9.3 billion euros.
- Sales for Nestlé's skin health division were €2.9 billion.
- For 2024, Galderma forecasts sales growth of 7% to 10%.
- Galderma plans to raise $2.3 billion (€2.1 billion) through its IPO
Ipsen's commitment to the area of rare diseases - 29/02/2024
Performance and strategies of the biopharmaceutical company Ipsen in 2023: 1. **Increase in sales:** In 2023, Ipsen recorded an increase in global sales of 3.4% over the previous year. 2. **Operating margin:** The company recorded an operating margin of 26.1%, which shows an increase of 2% compared to 2022. 3. **Growth factors:** Growth was supported by the company's historical assets, new drugs, pipeline expansion, and accelerated investment in research and development, particularly benefited by recent acquisitions focused on the area of rare diseases. 4. **Entry into the rare disease area:** In 2023, Ipsen acquired Albireo, a leading developer of bile acid modulators for the treatment of pediatric and adult cholestatic liver disease, bringing odevixibat, the first approved treatment against progressive familial intrahepatic cholestasis (Pfic), to the market. 5. **Future Plans:** By 2024, Ipsen plans to launch four innovative therapies worldwide and expand its pipeline, supported by an external innovation strategy in its three core therapeutic areas. 6. **Rare disease commitment:** With new developments such as odevixibat and an evolving pipeline, Ipsen marks its official entry into the rare disease field, aiming to bring therapeutic innovations that can change the course of disease, with a focus on drugs with novel mechanisms of action.
Botox: botulinum toxin boosts pharma's bottom line - 02/08/2023
- The United States accounts for half of the global botulinum toxin market.
- Last year, Botox accounted for $5.2 billion in worldwide sales for AbbVie, with equal shares between aesthetics (+21% excluding currency effect) and therapeutics (+13%).
- In the United States, Dysport (Ipsen) has only 5% of the therapeutic market, compared with 30% in France.
- In aesthetics in the US, Ipsen has an estimated share of between 20% and 25%.
- Of the French laboratory Ipsen's half-year sales of 1.5 billion euros (+7%), 319 million (+32%) come from botulinum toxin sold in therapeutics and, in some countries, in aesthetics.
- Botox holds 40% to 50% of the therapeutic market in France, compared with 30% for Ipsen.
Companies quoted in this study
This study contains a complete overview of the companies in the market, with the latest figures and news for each company. :
Choosing this study means :
Access to more than 35 hours of work
Our studies are the result of over 35 hours of research and analysis. Using our studies allows you to devote more time and added value to your projects.
Benefit from 6 years' experience and over 1,500 industry reports already produced
Our expertise enables us to produce comprehensive studies in all sectors, including niche and emerging markets.
Our know-how and methodology enable us to produce reports that offer unique value for money.
Access to several thousand articles and paid-for data
Businesscoot has access to all the paid economic press as well as exclusive databases to carry out its market research (over 30,000 articles and private sources).
To enhance our research, our analysts also use web indicators (semrush, trends, etc.) to identify market trends and company strategies. (Consult our paying sources)
Guaranteed support after your purchase
A team dedicated to after-sales service, to guarantee you a high level of satisfaction. +44 238 097 0676
A digital format designed for our users
Not only do you have access to a PDF, but also to a digital version designed for our customers. This version gives you access to sources, data in Excel format and graphics. The content of the study can therefore be easily retrieved and adapted for your specific needs.
Our offers :
the aesthetic medicine market | France
- What are the figures on the size and growth of the market?
- What is driving the growth of the market and its evolution?
- What is the positioning of companies in the value chain?
- Data from several dozen databases
Pack 5 études (-15%) France
- 5 études au prix de 75,6€HT par étude à choisir parmi nos 800 titres sur le catalogue France pendant 12 mois
- Conservez -15% sur les études supplémentaires achetées
- Choisissez le remboursement des crédits non consommés au terme des 12 mois (durée du pack)
Consultez les conditions du pack et de remboursement des crédits non consommés.
Our customer references
They have consulted our studies
Discover the opinions (+500)
Malcolm Vincent
Astoria Finance
Gregoire de Castelnau
Stags Participations
Timothé Huignard
PWC
Paul-Alexis Kebabtchieff
BCG
Aymeric Granet
Publicis Consultant
interviews & case studies
All interviews and case studies (45)
